Metabasis Therapeutics, Inc. is a biopharmaceutical company that engages in the discovery and development of drugs for chronic diseases involving pathways in the liver. The company provides products primarily for metabolic diseases, such as diabetes, hyperlipidemia, and liver diseases, including hepatitis and liver cancer. The company's pipeline candidates include MB07133 (for the treatment of primary liver cancer), MB07803 (for the treatment of type-II diabetes), and MB07811 (for the management of hyperlipidemia), all of which are in early-to-mid stages of clinical development. Metabasis received disappointing news in July 2007 related to the clinical development of two mid-stage candidates - CS-917 (for the treatment of type-II diabetes) and pradefovir (for the treatment of hepatitis B). While CS-917 failed to achieve the primary endpoint in a phase IIb trial, results from toxicology studies for pradefovir showed a higher dose-related incidence of cancer. The pradefovir news resulted in the termination of the company's development and commercialization agreement with Schering-Plough. As far as CS-917 is concerned, Metabasis announced that it will not continue with the development of the candidate.
Metabasis Therapeutics has strategic alliances with several larger pharmaceutical companies, including Valeant Pharmaceuticals, Daiichi Sankyo Co., Ltd., and Merck & Co. These collaborations helped Metabasis generate $4.4 million in revenues in 2006. Metabasis Therapeutics, Inc. is based in La Jolla, California.